ID=wsj_0463.1 PARSER=GOLD NUMPARSE=1
(<T S[dcl] 0 2> (<T S[dcl] 1 2> (<T NP 0 1> (<T N 1 2> (<L N/N NNP NNP Genentech N_181/N_181>) (<L N NNP NNP Inc. N>) ) ) (<T S[dcl]\NP 0 2> (<L (S[dcl]\NP)/S[dcl] VBD VBD said (S[dcl]\NP_8)/S[dcl]_9>) (<T S[dcl] 1 2> (<T NP 0 2> (<T NP 1 2> (<L NP[nb]/N DT DT the NP[nb]_142/N_142>) (<T N 1 2> (<L N/N NNP NNP West N_137/N_137>) (<T N 1 2> (<L N/N NNP NNP German N_130/N_130>) (<L N NN NN distributor N>) ) ) ) (<T NP\NP 0 2> (<L (NP\NP)/NP IN IN of (NP_150\NP_150)/NP_151>) (<T NP 1 2> (<L NP[nb]/N PRP$ PRP$ its NP[nb]_172/N_172>) (<T N 1 2> (<L N/N NN NN heart N_167/N_167>) (<T N 1 2> (<L N/N NN NN drug N_160/N_160>) (<L N NNP NNP TPA N>) ) ) ) ) ) (<T S[dcl]\NP 0 2> (<T (S[dcl]\NP)/PP 0 2> (<L ((S[dcl]\NP)/PP)/NP VBD VBD reached ((S[dcl]\NP_18)/PP_19)/NP_20>) (<T NP 1 2> (<L NP[nb]/N DT DT a NP[nb]_41/N_41>) (<T N 1 2> (<L N/N NN NN joint N_36/N_36>) (<T N 1 2> (<L N/N NN NN marketing N_29/N_29>) (<L N NN NN agreement N>) ) ) ) ) (<T PP 0 2> (<L PP/NP IN IN with PP/NP_46>) (<T NP 0 2> (<T NP 1 2> (<L NP[nb]/N DT DT a NP[nb]_53/N_53>) (<L N NN NN subsidiary N>) ) (<T NP\NP 0 2> (<L (NP\NP)/NP IN IN of (NP_61\NP_61)/NP_62>) (<T NP 0 2> (<T NP 0 2> (<T NP 0 1> (<T N 1 2> (<L N/N NNP NNP Hoechst N_71/N_71>) (<L N NNP NNP AG N>) ) ) (<L , , , , ,>) ) (<T NP\NP 0 2> (<L (NP\NP)/(S[dcl]\NP) WDT WDT which (NP_84\NP_84)/(S[dcl]_85\NP_84:B)_85>) (<T S[dcl]\NP 0 2> (<L (S[dcl]\NP)/NP VBZ VBZ makes (S[dcl]\NP_92)/NP_93>) (<T NP 1 2> (<L NP[nb]/N DT DT the NP[nb]_121/N_121>) (<T N 1 2> (<L N/N JJ JJ rival N_116/N_116>) (<T N 1 2> (<L N/N JJ JJ anti-clotting N_109/N_109>) (<T N 1 2> (<L N/N NN NN agent N_102/N_102>) (<L N NNP NNP streptokinase N>) ) ) ) ) ) ) ) ) ) ) ) ) ) ) (<L . . . . .>) ) 
ID=wsj_0463.2 PARSER=GOLD NUMPARSE=1
(<T S[dcl] 0 2> (<T S[dcl] 1 2> (<T NP 1 2> (<L NP[nb]/N DT DT The NP[nb]_373/N_373>) (<T N 1 2> (<L N/N NN NN biotechnology N_368/N_368>) (<L N NN NN concern N>) ) ) (<T S[dcl]\NP 0 2> (<L (S[dcl]\NP)/S[dcl] VBD VBD said (S[dcl]\NP_171)/S[dcl]_172>) (<T S[dcl] 1 2> (<T NP 0 2> (<T NP 1 2> (<L NP[nb]/N DT DT the NP[nb]_255/N_255>) (<L N NN NN agreement N>) ) (<T NP\NP 0 2> (<L (NP\NP)/NP IN IN between (NP_263\NP_263)/NP_264>) (<T NP 0 2> (<T NP 0 2> (<T NP 0 2> (<T NP 1 2> (<L NP[nb]/N PRP$ PRP$ its NP[nb]_292/N_292>) (<T N 1 2> (<L N/N NN NN longtime N_287/N_287>) (<T N 1 2> (<L N/N NNP NNP West N_280/N_280>) (<T N 1 2> (<L N/N NNP NNP German N_273/N_273>) (<L N NN NN distributor N>) ) ) ) ) (<T NP[conj] 1 2> (<L , , , , ,>) (<T NP 1 2> (<T NP[nb]/N 1 2> (<T NP 0 1> (<L N NNP NNP Boehringer-Ingleheim N>) ) (<L (NP[nb]/N)\NP POS POS 's (NP[nb]_329/N_329)\NP_330>) ) (<T N 1 2> (<L N/N NNP NNP Dr. N_322/N_322>) (<T N 1 2> (<L N/N NNP NNP Karl N_315/N_315>) (<T N 1 2> (<L N/N NNP NNP Thomae N_308/N_308>) (<T N 1 2> (<L N/N NNP NNP G.m.b.H. N_301/N_301>) (<L N NN NN subsidiary N>) ) ) ) ) ) ) ) (<L , , , , ,>) ) (<T NP[conj] 1 2> (<L conj CC CC and conj>) (<T NP 1 2> (<T NP[nb]/N 1 2> (<T NP 0 1> (<L N NNP NNP Hoechst N>) ) (<L (NP[nb]/N)\NP POS POS 's (NP[nb]_353/N_353)\NP_354>) ) (<T N 1 2> (<L N/N NNP NNP Behringwerke N_346/N_346>) (<L N NN NN subsidiary N>) ) ) ) ) ) ) (<T S[dcl]\NP 0 2> (<L (S[dcl]\NP)/NP VBD VBD was (S[dcl]\NP_179)/NP_180>) (<T NP 1 2> (<L NP[nb]/N DT DT an NP[nb]_248/N_248>) (<T N 0 2> (<L N NN NN attempt N>) (<T N\N 0 1> (<T S[to]\NP 0 2> (<L (S[to]\NP)/(S[b]\NP) TO TO to (S[to]\NP_191)/(S[b]_192\NP_191:B)_192>) (<T S[b]\NP 0 2> (<L (S[b]\NP)/NP VB VB expand (S[b]\NP_199)/NP_200>) (<T NP 0 2> (<T NP 1 2> (<L NP[nb]/N DT DT the NP[nb]_207/N_207>) (<L N NN NN market N>) ) (<T NP\NP 0 2> (<L (NP\NP)/NP IN IN for (NP_215\NP_215)/NP_216>) (<T NP 0 2> (<T NP 0 1> (<T N 1 2> (<L N/N NN NN blood-clot N_225/N_225>) (<L N NNS NNS drugs N>) ) ) (<T NP\NP 0 2> (<L (NP\NP)/NP IN IN in (NP_234\NP_234)/NP_235>) (<T NP 0 1> (<L N NN NN general N>) ) ) ) ) ) ) ) ) ) ) ) ) ) ) (<L . . . . .>) ) 
ID=wsj_0463.3 PARSER=GOLD NUMPARSE=1
(<T S[dcl] 0 2> (<T S[dcl] 1 2> (<T NP 1 2> (<L NP[nb]/N DT DT A NP[nb]_330/N_330>) (<T N 1 2> (<L N/N NNP NNP Genentech N_325/N_325>) (<L N NN NN spokeswoman N>) ) ) (<T S[dcl]\NP 0 2> (<L (S[dcl]\NP)/S[dcl] VBD VBD said (S[dcl]\NP_180)/S[dcl]_181>) (<T S[dcl] 1 2> (<T NP 1 2> (<L NP[nb]/N DT DT the NP[nb]_316/N_316>) (<L N NN NN agreement N>) ) (<T S[dcl]\NP 0 2> (<L (S[dcl]\NP)/S[for] VBZ VBZ calls (S[dcl]\NP_188)/S[for]_189>) (<T S[for] 0 2> (<T S[for]/(S[to]\NP) 0 2> (<L (S[for]/(S[to]\NP))/NP IN IN for (S[for]/(S[to]_198\NP_195:B)_198)/NP_195>) (<T NP 0 1> (<L N NNP NNP Hoechst N>) ) ) (<T S[to]\NP 0 2> (<L (S[to]\NP)/(S[b]\NP) TO TO to (S[to]\NP_211)/(S[b]_212\NP_211:B)_212>) (<T S[b]\NP 0 2> (<L (S[b]\NP)/NP VB VB promote (S[b]\NP_219)/NP_220>) (<T (S\NP)\((S\NP)/NP) 1 2> (<T (S\NP)\((S\NP)/NP) 0 2> (<T (S\NP)\((S\NP)/NP) 0 1> (<T NP 0 1> (<L N NNP NNP TPA N>) ) ) (<T (S\NP)\(S\NP) 0 2> (<L ((S\NP)\(S\NP))/NP IN IN for ((S_298\NP_293)_298\(S_298\NP_293)_298)/NP_299>) (<T NP 0 1> (<T N 1 2> (<L N/N NN NN heart N_308/N_308>) (<L N NNS NNS patients N>) ) ) ) ) (<T (S\NP)\((S\NP)/NP)[conj] 1 2> (<L conj CC CC and conj>) (<T (S\NP)\((S\NP)/NP) 0 2> (<T (S\NP)\((S\NP)/NP) 0 1> (<T NP 0 1> (<L N NNP NNP streptokinase N>) ) ) (<T (S\NP)\(S\NP) 0 2> (<L ((S\NP)\(S\NP))/NP IN IN for ((S_249\NP_244)_249\(S_249\NP_244)_249)/NP_250>) (<T NP 0 1> (<T N 1 2> (<L N/N JJ JJ other N_266/N_266>) (<T N 1 2> (<L N/N JJ JJ clot-reducing N_259/N_259>) (<L N NNS NNS purposes N>) ) ) ) ) ) ) ) ) ) ) ) ) ) ) (<L . . . . .>) ) 
